Loxo Oncology (LOXO) Reaches $82.85 After 5.00% Down Move; Shorts at Enanta Pharmaceuticals (ENTA) Lowered By 0.38%

November 8, 2017 - By Dolores Ford

Enanta Pharmaceuticals Incorporated (NASDAQ:ENTA) had a decrease of 0.38% in short interest. ENTA’s SI was 1.18 million shares in November as released by FINRA. Its down 0.38% from 1.18M shares previously. With 130,700 avg volume, 9 days are for Enanta Pharmaceuticals Incorporated (NASDAQ:ENTA)’s short sellers to cover ENTA’s short positions. The SI to Enanta Pharmaceuticals Incorporated’s float is 8.93%. About 163,092 shares traded or 8.58% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since November 8, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.

The stock of Loxo Oncology Inc (NASDAQ:LOXO) is a huge mover today! About 398,809 shares traded or 9.38% up from the average. Loxo Oncology Inc (NASDAQ:LOXO) has risen 77.12% since November 8, 2016 and is uptrending. It has outperformed by 60.42% the S&P500.The move comes after 5 months negative chart setup for the $2.48 billion company. It was reported on Nov, 8 by Barchart.com. We have $78.71 PT which if reached, will make NASDAQ:LOXO worth $124.00M less.

Among 8 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Loxo Oncology Inc had 25 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, March 16. As per Tuesday, August 8, the company rating was maintained by Stifel Nicolaus. Citigroup upgraded Loxo Oncology Inc (NASDAQ:LOXO) on Monday, June 5 to “Buy” rating. The rating was maintained by Citigroup with “Buy” on Wednesday, March 16. The stock of Loxo Oncology Inc (NASDAQ:LOXO) earned “Buy” rating by Morgan Stanley on Monday, June 19. As per Tuesday, August 4, the company rating was maintained by Oppenheimer. Stifel Nicolaus maintained the shares of LOXO in report on Thursday, November 2 with “Buy” rating. The firm has “Sell” rating given on Friday, August 28 by Zacks. On Monday, June 5 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm earned “Outperform” rating on Thursday, August 27 by Cowen & Co.

Loxo Oncology, Inc. is a biopharmaceutical company. The company has market cap of $2.48 billion. The Firm is focused on development of medicines for patients with genetically defined cancers. It currently has negative earnings. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Investors sentiment increased to 3.83 in 2017 Q2. Its up 1.64, from 2.19 in 2017Q1. It is positive, as 5 investors sold Loxo Oncology Inc shares while 18 reduced holdings. 43 funds opened positions while 45 raised stakes. 57.37 million shares or 120.56% more from 26.01 million shares in 2017Q1 were reported. Lord Abbett & Ltd Liability has 0.18% invested in Loxo Oncology Inc (NASDAQ:LOXO). Sg Americas Secs Lc holds 2,847 shares or 0% of its portfolio. Alyeska Invest Grp Lp has invested 0.04% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO). The Pennsylvania-based Federated Invsts Inc Pa has invested 0.01% in Loxo Oncology Inc (NASDAQ:LOXO). Vident Invest Advisory Limited Liability Com invested in 0.04% or 5,906 shares. Pictet Asset Limited accumulated 210,766 shares. Baker Bros Advsrs L P holds 0.1% or 138,312 shares in its portfolio. Citigroup Inc has 8,349 shares. Aisling Cap Limited Liability Corporation owns 4.19 million shares. Boothbay Fund Mgmt Limited Liability reported 0.06% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO). Opaleye Mngmt Incorporated holds 4.35% or 130,000 shares. State Of Wisconsin Inv Board reported 14,000 shares stake. Morgan Stanley accumulated 87,194 shares. Schwab Charles Invest Management holds 0.01% or 81,716 shares in its portfolio. Driehaus Capital Mgmt Lc invested 1.05% in Loxo Oncology Inc (NASDAQ:LOXO).

Since May 22, 2017, it had 0 insider purchases, and 1 insider sale for $326,936 activity. 7,250 shares were sold by Flaherty Keith T., worth $326,936.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $905.84 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was upgraded by JMP Securities to “Mkt Outperform” on Friday, October 23. The rating was downgraded by Zacks to “Buy” on Friday, August 7. The stock has “Hold” rating by Robert W. Baird on Friday, October 20. Robert W. Baird maintained Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Tuesday, August 8 with “Neutral” rating. As per Tuesday, August 9, the company rating was maintained by JP Morgan. The company was downgraded on Thursday, April 28 by JMP Securities. The firm earned “Buy” rating on Friday, October 20 by RBC Capital Markets. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Underweight” rating given on Friday, October 23 by Barclays Capital. TheStreet downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Saturday, August 8 to “Buy” rating. The firm has “Hold” rating given on Friday, September 15 by Robert W. Baird.

Investors sentiment decreased to 0.85 in Q2 2017. Its down 0.09, from 0.94 in 2017Q1. It turned negative, as 12 investors sold Enanta Pharmaceuticals Inc shares while 42 reduced holdings. 13 funds opened positions while 33 raised stakes. 11.77 million shares or 2.06% more from 11.53 million shares in 2017Q1 were reported. Weiss Multi holds 30,000 shares or 0.05% of its portfolio. Alliancebernstein L P reported 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Numeric Invsts Ltd Liability Corp accumulated 76,602 shares. Invesco Ltd reported 81,137 shares stake. Ameritas Invest Prns has 1,235 shares. 847,021 are owned by Vanguard Group. Credit Suisse Ag holds 0% or 28,651 shares. Royal Natl Bank Of Canada invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Meeder Asset Management holds 0% or 155 shares. Moreover, Int Gp has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Virginia Retirement Sys Et Al holds 65,900 shares or 0.03% of its portfolio. Armistice Capital Llc holds 1.21% or 264,000 shares in its portfolio. California State Teachers Retirement System has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). D E Shaw And Co stated it has 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Gotham Asset Mgmt Ltd Liability holds 0.01% or 19,268 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: